Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer

(2020) Xin Zhang et al.   Frontiers in Immunology

Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma

(2020) Bin Du et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

(2020) Rilan Bai et al.   Biomarker Research

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

(2019) Cem Simsek et al.   Journal of Oncology

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

(2019) Leonie Voorwerk et al.   NATURE MEDICINE

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression

(2019) Antonino Bruno et al.   Frontiers in Immunology

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages

(2018) Sachin Kumar Deshmukh et al.   Scientific Reports

Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy

(2016) Y. Shaked et al.   CANCER RESEARCH

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Naiyer A. Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect

(2016) Guido Bocci et al.   Nature Reviews Clinical Oncology

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

(2016) Joohee Sul et al.   ONCOLOGIST

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Metronomic chemotherapy from rationale to clinical studies: A dream or reality?

(2015) Antonio Gnoni et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

(2015) G. Giaccone et al.   EUROPEAN JOURNAL OF CANCER

GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery

(2014) Theodoros Karampelas et al.   BIOCONJUGATE CHEMISTRY

Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model

(2014) Junjie Wu et al.   CANCER LETTERS

Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis

(2014) Dinesh Vyas et al.   OncoTargets and Therapy

Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy

(2014) Erez Hasnis et al.   NEOPLASIA

Treatment of Stage IV Non-small Cell Lung Cancer

(2013) Mark A. Socinski et al.   CHEST

Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

(2013) S. E. Pratt et al.   MOLECULAR CANCER THERAPEUTICS

Gemcitabine: A Critical Nucleoside for Cancer Therapy

(2012) D. S. Gesto et al.   CURRENT MEDICINAL CHEMISTRY

Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy

(2012) Mariana S. Nars et al.   INTERNATIONAL JOURNAL OF CANCER

Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

(2011) G. Francia et al.   MOLECULAR CANCER THERAPEUTICS

Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine

(2009) David M. Bender et al.   JOURNAL OF MEDICINAL CHEMISTRY

Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy

(2008) S. A. Veltkamp et al.   ONCOLOGIST